Considering "clonality": A regulatory perspective on the importance of the clonal derivation of mammalian cell banks in biopharmaceutical development.

There has been much recent focus on the regulatory emphasis and the relative importance surrounding clonal derivation of mammalian production cell lines used in the manufacture of recombinant DNA-derived biopharmaceuticals. This interest has led to an ongoing discussion between regulators and industry on how this topic is evaluated and the role it plays in the development of a new biopharmaceutical. Herein the authors describe that the clonal derivation of the production cell line is a factor with potential impact on product quality, and thus should not be considered separately from, but rather in the context of all elements comprising the control strategy necessary to support approval of a regulatory application. Considerations for how clonal derivation of cell banks and clonal variation thereof may be viewed during the lifecycle of a biopharmaceutical product is provided.

[1]  H. Waldmann,et al.  Limiting Dilution Analysis of Cells in the Immune System , 1980 .

[2]  C. Frye,et al.  Transgene copy number distribution profiles in recombinant CHO cell lines revealed by single cell analyses , 2012, Biotechnology and bioengineering.

[3]  Jürgen Fieder,et al.  A single-step FACS sorting strategy in conjunction with fluorescent vital dye imaging efficiently assures clonality of biopharmaceutical production cell lines. , 2017, Biotechnology journal.

[4]  T. Munro,et al.  Accelerating patient access to novel biologics using stable pool‐derived product for non‐clinical studies and single clone‐derived product for clinical studies , 2017, Biotechnology progress.

[5]  F. Wurm.  CHO Quasispecies—Implications for Manufacturing Processes , 2013 .

[6]  Jianwei Zhu,et al.  Mammalian cell protein expression for biopharmaceutical production. , 2012, Biotechnology advances.

[7]  B. Snedecor,et al.  Slashing the timelines: Opting to generate high‐titer clonal lines faster via viability‐based single cell sorting , 2016, Biotechnology progress.

[8]  Raymond Davis,et al.  Antibody expression stability in CHO clonally derived cell lines and their subclones: Role of methylation in phenotypic and epigenetic heterogeneity , 2018, Biotechnology progress.

[9]  Neil A. McCracken,et al.  Evaluation of piggyBac‐mediated CHO pools to enable material generation to support GLP toxicology studies , 2017, Biotechnology progress.

[10]  Reb J. Russell,et al.  Comparative study of therapeutic antibody candidates derived from mini‐pool and clonal cell lines , 2017, Biotechnology progress.

[11]  Y. Zhou,et al.  Beating the odds: The poisson distribution of all input cells during limiting dilution grossly underestimates whether a cell line is clonally‐derived or not , 2018, Biotechnology progress.

[12]  C. Frye,et al.  Industry view on the relative importance of "clonality" of biopharmaceutical-producing cell lines. , 2016, Biologicals : journal of the International Association of Biological Standardization.

[13]  Jorge Quiroz,et al.  Statistical analysis of data from limiting dilution cloning to assess monoclonality in generating manufacturing cell lines , 2016, Biotechnology progress.

[14]  Florian M Wurm,et al.  First CHO genome , 2011, Nature Biotechnology.

[15]  GUIDELINE ON DEVELOPMENT , PRODUCTION , CHARACTERISATION AND SPECIFICATIONS FOR MONOCLONAL ANTIBODIES AND RELATED PRODUCTS , 2009 .

[16]  Edward J. O'Brien,et al.  Genomic landscapes of Chinese hamster ovary cell lines as revealed by the Cricetulus griseus draft genome , 2013, Nature Biotechnology.

[17]  Niranjan Nagarajan,et al.  Mammalian Systems Biotechnology Reveals Global Cellular Adaptations in a Recombinant CHO Cell Line. , 2017, Cell systems.

[18]  Mohamed Al-Rubeai,et al.  Selection methods for high-producing mammalian cell lines. , 2007, Trends in biotechnology.

[19]  L. Nielsen,et al.  RNA-Seq Highlights High Clonal Variation in Monoclonal Antibody Producing CHO Cells. , 2018, Biotechnology journal.

[20]  Kelvin H. Lee,et al.  The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line , 2011, Nature Biotechnology.

[21]  H. Hansen,et al.  Improving the secretory capacity of Chinese hamster ovary cells by ectopic expression of effector genes: Lessons learned and future directions. , 2017, Biotechnology advances.

[22]  Jingkui Chen,et al.  Analyzing Clonal Variation of Monoclonal Antibody-Producing CHO Cell Lines Using an In Silico Metabolomic Platform , 2014, PloS one.

[23]  N. Mermod,et al.  IL‐17F co‐ ;expression improves cell growth characteristics and enhances recombinant protein production during CHO cell line engineering , 2013, Biotechnology and bioengineering.

[24]  Zhong Liu,et al.  A high-throughput automated platform for the development of manufacturing cell lines for protein therapeutics. , 2011, Journal of visualized experiments : JoVE.

[25]  R Staszewski,et al.  Murphy's law of limiting dilution cloning. , 1990, Statistics in medicine.

[26]  P. Bondarenko,et al.  Metabolic markers associated with high mannose glycan levels of therapeutic recombinant monoclonal antibodies. , 2015, Journal of biotechnology.

[27]  Mark Plavsic,et al.  Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products , 2017, Handbook of Pharmaceutical Manufacturing Formulations, Second Edition.

[28]  B. Snedecor,et al.  Probing the importance of clonality: Single cell subcloning of clonally derived CHO cell lines yields widely diverse clones differing in growth, productivity, and product quality , 2018, Biotechnology progress.

[29]  Griffin,et al.  Points to consider in the manufacture and testing of monoclonal antibody products for human use (1997). U.S. Food and Drug Administration Center for Biologics Evaluation and Research. , 1997, Journal of immunotherapy.

[30]  J. Dumont,et al.  Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives , 2015, Critical reviews in biotechnology.

[31]  F. Leisch,et al.  Karyotype variation of CHO host cell lines over time in culture characterized by chromosome counting and chromosome painting , 2018, Biotechnology and bioengineering.

[32]  Karin Anderson,et al.  Analytical subcloning of a clonal cell line demonstrates cellular heterogeneity that does not impact process consistency or robustness , 2018, Biotechnology progress.

[33]  B. Snedecor,et al.  A strategy to accelerate protein production from a pool of clones in Chinese hamster ovary cells for toxicology studies , 2017, Biotechnology progress.

[34]  A. Garnier,et al.  Fluorescent labeling in semi-solid medium for selection of mammalian cells secreting high-levels of recombinant proteins , 2009, BMC biotechnology.

[35]  G. M. Lee,et al.  Clonal variability within dihydrofolate reductase-mediated gene amplified Chinese hamster ovary cells: stability in the absence of selective pressure. , 1998, Biotechnology and bioengineering.

[36]  F. Wurm,et al.  Cloning of CHO Cells, Productivity and Genetic Stability—A Discussion , 2017 .

[37]  H. Coller,et al.  Statistical analysis of repetitive subcloning by the limiting dilution technique with a view toward ensuring hybridoma monoclonality. , 1983, Hybridoma.

[38]  Li Zhuang,et al.  Sequential screening by ClonePix FL and intracellular staining facilitate isolation of high producer cell lines for monoclonal antibody manufacturing. , 2017, Journal of immunological methods.

[39]  C. Frye,et al.  Improving the efficiency of CHO cell line generation using glutamine synthetase gene knockout cells , 2012, Biotechnology and bioengineering.